Is ANRO or DNLI more profitable?

Alto Neuroscience's return on equity of -47.22% beat Denali Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Alto Neuroscience N/A -47.22% -38.81% Denali Therapeutics N/A -53.53% -44.26%

Does the media refer more to ANRO or DNLI?

In the previous week, Denali Therapeutics had 9 more articles in the media than Alto Neuroscience. MarketBeat recorded 13 mentions for Denali Therapeutics and 4 mentions for Alto Neuroscience. Alto Neuroscience's average media sentiment score of 0.66 beat Denali Therapeutics' score of 0.22 indicating that Alto Neuroscience is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alto Neuroscience 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Denali Therapeutics 4 Very Positive mention(s) 3 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer ADPT or ANRO?

In the previous week, Adaptive Biotechnologies had 3 more articles in the media than Alto Neuroscience. MarketBeat recorded 7 mentions for Adaptive Biotechnologies and 4 mentions for Alto Neuroscience. Adaptive Biotechnologies' average media sentiment score of 0.85 beat Alto Neuroscience's score of 0.66 indicating that Adaptive Biotechnologies is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Adaptive Biotechnologies 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Alto Neuroscience 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to ARQT or ANRO?

In the previous week, Arcutis Biotherapeutics had 33 more articles in the media than Alto Neuroscience. MarketBeat recorded 37 mentions for Arcutis Biotherapeutics and 4 mentions for Alto Neuroscience. Arcutis Biotherapeutics' average media sentiment score of 0.76 beat Alto Neuroscience's score of 0.66 indicating that Arcutis Biotherapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arcutis Biotherapeutics 7 Very Positive mention(s) 3 Positive mention(s) 10 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Alto Neuroscience 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer ANRO or OGN?

In the previous week, Alto Neuroscience had 1 more articles in the media than Organon & Co.. MarketBeat recorded 4 mentions for Alto Neuroscience and 3 mentions for Organon & Co.. Organon & Co.'s average media sentiment score of 0.68 beat Alto Neuroscience's score of 0.66 indicating that Organon & Co. is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alto Neuroscience 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Organon & Co. 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor LEGN or ANRO?

In the previous week, Legend Biotech had 1 more articles in the media than Alto Neuroscience. MarketBeat recorded 5 mentions for Legend Biotech and 4 mentions for Alto Neuroscience. Legend Biotech's average media sentiment score of 1.31 beat Alto Neuroscience's score of 0.66 indicating that Legend Biotech is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Legend Biotech 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Alto Neuroscience 1 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Alto Neuroscience (ANRO) Competitors

$28.61 +0.14 (+0.49%)

Closing price 08/7/2026 03:59 PM Eastern

Extended Trading

$27.98 -0.63 (-2.20%)

As of 08/7/2026 07:34 PM Eastern

Compare

ANRO vs. DNLI, ADPT, ARQT, OGN, and LEGN

Should you buy Alto Neuroscience stock or one of its competitors? MarketBeat compares Alto Neuroscience with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Alto Neuroscience include Denali Therapeutics (DNLI), Adaptive Biotechnologies (ADPT), Arcutis Biotherapeutics (ARQT), Organon & Co. (OGN), and Legend Biotech (LEGN).

How does Alto Neuroscience compare to Denali Therapeutics?

Alto Neuroscience (NYSE:ANRO) and Denali Therapeutics (NASDAQ:DNLI) are both healthcare companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, profitability, analyst recommendations, risk, dividends, earnings and valuation.

Alto Neuroscience's return on equity of -47.22% beat Denali Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alto Neuroscience	N/A	-47.22%	-38.81%
Denali Therapeutics	N/A	-53.53%	-44.26%

In the previous week, Denali Therapeutics had 9 more articles in the media than Alto Neuroscience. MarketBeat recorded 13 mentions for Denali Therapeutics and 4 mentions for Alto Neuroscience. Alto Neuroscience's average media sentiment score of 0.66 beat Denali Therapeutics' score of 0.22 indicating that Alto Neuroscience is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alto Neuroscience	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Denali Therapeutics	4 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Alto Neuroscience has higher earnings, but lower revenue than Denali Therapeutics. Alto Neuroscience is trading at a lower price-to-earnings ratio than Denali Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alto Neuroscience	N/A	N/A	-$63.24M	-$2.42	N/A
Denali Therapeutics	$330.53M	11.92	-$512.54M	-$2.84	N/A

Alto Neuroscience currently has a consensus price target of $35.25, suggesting a potential upside of 23.21%. Denali Therapeutics has a consensus price target of $35.92, suggesting a potential upside of 44.65%. Given Denali Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Denali Therapeutics is more favorable than Alto Neuroscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alto Neuroscience	2 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.55
Denali Therapeutics	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	0 Strong Buy rating(s)	2.75

92.9% of Denali Therapeutics shares are owned by institutional investors. 11.3% of Alto Neuroscience shares are owned by insiders. Comparatively, 9.7% of Denali Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Alto Neuroscience has a beta of 1.06, meaning that its share price is 6% more volatile than the broader market. Comparatively, Denali Therapeutics has a beta of 1.01, meaning that its share price is 1% more volatile than the broader market.

Summary

Alto Neuroscience and Denali Therapeutics tied by winning 7 of the 14 factors compared between the two stocks.

How does Alto Neuroscience compare to Adaptive Biotechnologies?

Adaptive Biotechnologies (NASDAQ:ADPT) and Alto Neuroscience (NYSE:ANRO) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, analyst recommendations, valuation, profitability, dividends, risk, media sentiment and institutional ownership.

Adaptive Biotechnologies presently has a consensus price target of $24.42, indicating a potential downside of 2.06%. Alto Neuroscience has a consensus price target of $35.25, indicating a potential upside of 23.21%. Given Alto Neuroscience's higher possible upside, analysts clearly believe Alto Neuroscience is more favorable than Adaptive Biotechnologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adaptive Biotechnologies	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Alto Neuroscience	2 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.55

Alto Neuroscience has a net margin of 0.00% compared to Adaptive Biotechnologies' net margin of -20.73%. Adaptive Biotechnologies' return on equity of -36.81% beat Alto Neuroscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Adaptive Biotechnologies	-20.73%	-36.81%	-13.77%
Alto Neuroscience	N/A	-47.22%	-38.81%

In the previous week, Adaptive Biotechnologies had 3 more articles in the media than Alto Neuroscience. MarketBeat recorded 7 mentions for Adaptive Biotechnologies and 4 mentions for Alto Neuroscience. Adaptive Biotechnologies' average media sentiment score of 0.85 beat Alto Neuroscience's score of 0.66 indicating that Adaptive Biotechnologies is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Adaptive Biotechnologies	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Alto Neuroscience	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

99.2% of Adaptive Biotechnologies shares are held by institutional investors. 5.7% of Adaptive Biotechnologies shares are held by insiders. Comparatively, 11.3% of Alto Neuroscience shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Adaptive Biotechnologies has higher revenue and earnings than Alto Neuroscience. Adaptive Biotechnologies is trading at a lower price-to-earnings ratio than Alto Neuroscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adaptive Biotechnologies	$308.08M	12.91	-$59.50M	-$0.41	N/A
Alto Neuroscience	N/A	N/A	-$63.24M	-$2.42	N/A

Adaptive Biotechnologies has a beta of 2.08, meaning that its share price is 108% more volatile than the broader market. Comparatively, Alto Neuroscience has a beta of 1.06, meaning that its share price is 6% more volatile than the broader market.

Summary

Adaptive Biotechnologies beats Alto Neuroscience on 10 of the 15 factors compared between the two stocks.

How does Alto Neuroscience compare to Arcutis Biotherapeutics?

Arcutis Biotherapeutics (NASDAQ:ARQT) and Alto Neuroscience (NYSE:ANRO) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, media sentiment, dividends, profitability, earnings, analyst recommendations, risk and valuation.

Arcutis Biotherapeutics presently has a consensus target price of $35.57, suggesting a potential upside of 40.65%. Alto Neuroscience has a consensus target price of $35.25, suggesting a potential upside of 23.21%. Given Arcutis Biotherapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Arcutis Biotherapeutics is more favorable than Alto Neuroscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arcutis Biotherapeutics	0 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.67
Alto Neuroscience	2 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.55

Arcutis Biotherapeutics has a beta of 1.49, meaning that its share price is 49% more volatile than the broader market. Comparatively, Alto Neuroscience has a beta of 1.06, meaning that its share price is 6% more volatile than the broader market.

Arcutis Biotherapeutics has higher revenue and earnings than Alto Neuroscience. Alto Neuroscience is trading at a lower price-to-earnings ratio than Arcutis Biotherapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arcutis Biotherapeutics	$463.98M	6.82	-$16.14M	$0.21	120.43
Alto Neuroscience	N/A	N/A	-$63.24M	-$2.42	N/A

Arcutis Biotherapeutics has a net margin of 6.15% compared to Alto Neuroscience's net margin of 0.00%. Arcutis Biotherapeutics' return on equity of 15.05% beat Alto Neuroscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arcutis Biotherapeutics	6.15%	15.05%	6.51%
Alto Neuroscience	N/A	-47.22%	-38.81%

In the previous week, Arcutis Biotherapeutics had 33 more articles in the media than Alto Neuroscience. MarketBeat recorded 37 mentions for Arcutis Biotherapeutics and 4 mentions for Alto Neuroscience. Arcutis Biotherapeutics' average media sentiment score of 0.76 beat Alto Neuroscience's score of 0.66 indicating that Arcutis Biotherapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arcutis Biotherapeutics	7 Very Positive mention(s)	3 Positive mention(s)	10 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Alto Neuroscience	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Arcutis Biotherapeutics beats Alto Neuroscience on 12 of the 13 factors compared between the two stocks.

How does Alto Neuroscience compare to Organon & Co.?

Alto Neuroscience (NYSE:ANRO) and Organon & Co. (NYSE:OGN) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, media sentiment, risk, profitability, institutional ownership, analyst recommendations, earnings and valuation.

Alto Neuroscience currently has a consensus target price of $35.25, suggesting a potential upside of 23.21%. Organon & Co. has a consensus target price of $11.40, suggesting a potential downside of 16.15%. Given Alto Neuroscience's stronger consensus rating and higher possible upside, equities research analysts clearly believe Alto Neuroscience is more favorable than Organon & Co..

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alto Neuroscience	2 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.55
Organon & Co.	2 Sell rating(s)	5 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.71

77.4% of Organon & Co. shares are owned by institutional investors. 11.3% of Alto Neuroscience shares are owned by company insiders. Comparatively, 1.6% of Organon & Co. shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Organon & Co. has a net margin of 3.41% compared to Alto Neuroscience's net margin of 0.00%. Organon & Co.'s return on equity of 88.97% beat Alto Neuroscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alto Neuroscience	N/A	-47.22%	-38.81%
Organon & Co.	3.41%	88.97%	6.03%

In the previous week, Alto Neuroscience had 1 more articles in the media than Organon & Co.. MarketBeat recorded 4 mentions for Alto Neuroscience and 3 mentions for Organon & Co.. Organon & Co.'s average media sentiment score of 0.68 beat Alto Neuroscience's score of 0.66 indicating that Organon & Co. is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Alto Neuroscience	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Organon & Co.	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Organon & Co. has higher revenue and earnings than Alto Neuroscience. Alto Neuroscience is trading at a lower price-to-earnings ratio than Organon & Co., indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alto Neuroscience	N/A	N/A	-$63.24M	-$2.42	N/A
Organon & Co.	$6.13B	0.58	$187M	$0.77	17.66

Alto Neuroscience has a beta of 1.06, indicating that its share price is 6% more volatile than the broader market. Comparatively, Organon & Co. has a beta of 1.55, indicating that its share price is 55% more volatile than the broader market.

Summary

Organon & Co. beats Alto Neuroscience on 10 of the 15 factors compared between the two stocks.

How does Alto Neuroscience compare to Legend Biotech?

Legend Biotech (NASDAQ:LEGN) and Alto Neuroscience (NYSE:ANRO) are both healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, earnings, risk, valuation, profitability, media sentiment, institutional ownership and dividends.

Alto Neuroscience has lower revenue, but higher earnings than Legend Biotech. Legend Biotech is trading at a lower price-to-earnings ratio than Alto Neuroscience, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Legend Biotech	$1.14B	3.38	-$296.80M	-$0.68	N/A
Alto Neuroscience	N/A	N/A	-$63.24M	-$2.42	N/A

70.9% of Legend Biotech shares are owned by institutional investors. 0.0% of Legend Biotech shares are owned by company insiders. Comparatively, 11.3% of Alto Neuroscience shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Legend Biotech has a beta of 0.37, meaning that its stock price is 63% less volatile than the broader market. Comparatively, Alto Neuroscience has a beta of 1.06, meaning that its stock price is 6% more volatile than the broader market.

In the previous week, Legend Biotech had 1 more articles in the media than Alto Neuroscience. MarketBeat recorded 5 mentions for Legend Biotech and 4 mentions for Alto Neuroscience. Legend Biotech's average media sentiment score of 1.31 beat Alto Neuroscience's score of 0.66 indicating that Legend Biotech is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Legend Biotech	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Alto Neuroscience	1 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Alto Neuroscience has a net margin of 0.00% compared to Legend Biotech's net margin of -21.98%. Legend Biotech's return on equity of -24.92% beat Alto Neuroscience's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Legend Biotech	-21.98%	-24.92%	-14.87%
Alto Neuroscience	N/A	-47.22%	-38.81%

Legend Biotech currently has a consensus price target of $55.29, indicating a potential upside of 166.44%. Alto Neuroscience has a consensus price target of $35.25, indicating a potential upside of 23.21%. Given Legend Biotech's higher probable upside, analysts plainly believe Legend Biotech is more favorable than Alto Neuroscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Legend Biotech	1 Sell rating(s)	5 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.53
Alto Neuroscience	2 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.55

Summary

Legend Biotech beats Alto Neuroscience on 9 of the 15 factors compared between the two stocks.

Get Alto Neuroscience News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ANRO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ANRO vs. The Competition

Export

Metric	Alto Neuroscience	Pharmaceuticals Industry	Healthcare Sector	NYSE Exchange
Market Cap	$1.01B	$11.85B	$7.01B	$24.19B
Dividend Yield	N/A	2.70%	2.58%	3.70%
P/E Ratio	-11.82	790.97	271.11	29.20
Price / Sales	N/A	743.77	590.29	167.25
Price / Cash	N/A	71.16	71.81	33.74
Price / Book	5.87	10.75	13.25	6.87
Net Income	-$63.24M	$2.78B	$3.45B	$1.06B
7 Day Performance	5.59%	3.36%	4.67%	2.91%
1 Month Performance	2.90%	-0.81%	-1.28%	2.94%
1 Year Performance	834.36%	192.86%	77.33%	20.40%

Alto Neuroscience Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ANRO Alto Neuroscience	2.0144 of 5 stars	$28.61 +0.5%	$35.25 +23.2%	+834.4%	$1.01B	N/A	N/A	N/A	Upcoming Earnings
DNLI Denali Therapeutics	2.7118 of 5 stars	$24.05 +2.0%	$35.17 +46.2%	+77.9%	$3.82B	$330.53M	N/A	430	News Coverage Positive News Earnings Report Analyst Forecast
ADPT Adaptive Biotechnologies	1.5072 of 5 stars	$22.52 -0.1%	$20.83 -7.5%	+104.3%	$3.60B	$276.98M	N/A	790	Analyst Forecast Gap Up
ARQT Arcutis Biotherapeutics	4.2533 of 5 stars	$28.42 +2.1%	$34.00 +19.6%	+71.2%	$3.55B	$415.62M	N/A	150	Trending News Earnings Report Analyst Forecast Insider Trade Analyst Revision
OGN Organon & Co.	1.5985 of 5 stars	$13.54 0.0%	$11.40 -15.8%	+47.5%	$3.55B	$6.16B	14.55	10,000	Dividend Announcement

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:ANRO) was last updated on 8/9/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Alto Neuroscience (ANRO) Competitors

ANRO vs. DNLI, ADPT, ARQT, OGN, and LEGN

How does Alto Neuroscience compare to Denali Therapeutics?

Summary

How does Alto Neuroscience compare to Adaptive Biotechnologies?

Summary

How does Alto Neuroscience compare to Arcutis Biotherapeutics?

Summary

How does Alto Neuroscience compare to Organon & Co.?

Summary

How does Alto Neuroscience compare to Legend Biotech?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANRO vs. The Competition

Alto Neuroscience Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Alto Neuroscience (ANRO) Competitors

ANRO vs. DNLI, ADPT, ARQT, OGN, and LEGN

How does Alto Neuroscience compare to Denali Therapeutics?

Is ANRO or DNLI more profitable?

Does the media refer more to ANRO or DNLI?

Which has higher earnings & valuation, ANRO or DNLI?

Do analysts rate ANRO or DNLI?

Do insiders and institutionals hold more shares of ANRO or DNLI?

Which has more volatility & risk, ANRO or DNLI?

Summary

How does Alto Neuroscience compare to Adaptive Biotechnologies?

Do analysts prefer ADPT or ANRO?

Is ADPT or ANRO more profitable?

Does the media prefer ADPT or ANRO?

Do insiders & institutionals have more ownership in ADPT or ANRO?

Which has stronger earnings and valuation, ADPT or ANRO?

Which has more volatility & risk, ADPT or ANRO?

Summary

How does Alto Neuroscience compare to Arcutis Biotherapeutics?

Do analysts recommend ARQT or ANRO?

Which has more risk and volatility, ARQT or ANRO?

Which has preferable earnings & valuation, ARQT or ANRO?

Is ARQT or ANRO more profitable?

Does the media refer more to ARQT or ANRO?

Summary

How does Alto Neuroscience compare to Organon & Co.?

Do analysts recommend ANRO or OGN?

Do insiders & institutionals hold more shares of ANRO or OGN?

Is ANRO or OGN more profitable?

Does the media prefer ANRO or OGN?

Which has higher earnings & valuation, ANRO or OGN?

Which has more risk and volatility, ANRO or OGN?

Summary

How does Alto Neuroscience compare to Legend Biotech?

Which has better earnings and valuation, LEGN or ANRO?

Do institutionals & insiders have more ownership in LEGN or ANRO?

Which has more risk and volatility, LEGN or ANRO?

Does the media favor LEGN or ANRO?

Is LEGN or ANRO more profitable?

Do analysts rate LEGN or ANRO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ANRO vs. The Competition

Alto Neuroscience Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools